Related Experiment Videos

[Angiogenic factors]

Nouvelle Revue Francaise D'Hematologie
|January 1, 1987
PubMed

Insights

Tumor angiogenesis, crucial for cancer growth, can be inhibited by factors like heparin. Heparin shows promise in regulating vascular cell growth, offering potential therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Angiogenesis, the formation of new blood vessels, is a critical process in tumor progression.
  • Significant research efforts have focused on identifying and characterizing tumor angiogenic factors (TAF).
  • The development of anti-angiogenic therapies is a key area in cancer treatment research.

Purpose:

  • To review the progress in understanding tumor angiogenesis, from factor identification to therapeutic inhibition.
  • To highlight the role of heparin as a potential inhibitor of angiogenesis.
  • To explore the pharmacological implications of heparin's interaction with growth factors and its effect on vascular cells.

Summary:

  • Over 14 years, research advanced from identifying tumor angiogenic factors (TAFs) to purifying, sequencing, and cloning a potent TAF.
  • Tumor angiogenesis can be effectively inhibited by various agents, including cartilage-derived factors, protamine, and a combination of heparin and cortisone.
  • Heparin demonstrates a significant pharmacological role in angiogenesis by interacting with growth factors and influencing the proliferation of endothelial cells, smooth muscle cells, and fibroblasts.

Impact:

  • Understanding the mechanisms of angiogenesis and its inhibition provides a foundation for developing novel cancer therapies.
  • Heparin's demonstrated effects on vascular cell growth suggest its potential as a therapeutic agent in managing angiogenesis-dependent diseases.
  • Further research into heparin's interactions could unlock new strategies for controlling tumor growth and metastasis.

Related Concept Videos